|
|
|
|
|
|
Sponsored by: |
Department of Veterans Affairs |
Information provided by: | Department of Veterans Affairs |
ClinicalTrials.gov Identifier: | NCT00240227 |
This double-blind placebo controlled crossover pilot trial will test the hypothesis that prazosin, an alpha-1 adrenergic receptor antagonist, reduces craving for their drug of choice in cocaine-dependent and alcohol-dependent veterans. Both the study medication period and the placebo period are each 4 weeks in duration.
Condition | Intervention |
Alcoholism Cocaine Dependence |
Drug: Prazosin |
MedlinePlus related topics: | Alcoholism |
ChemIDplus related topics: | 8-Azabicyclo(3.2.1)octane-2-carboxylic acid, 3-(benzoyloxy)-8-methyl-, methyl ester, (1R-(exo,exo))- Cocaine hydrochloride Ethanol Prazosin Prazosin hydrochloride |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | The Role of the Alpha 1-Adrenergic Antagonist, Prazosin, in the Reduction of Craving and Relapse in Alcohol and Cocaine-Dependent Individuals: a Double-Blind, Randomized, Controlled Clinical Trial |
Estimated Enrollment: | 32 |
Study Start Date: | April 2004 |
Estimated Study Completion Date: | September 2009 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1
Prazosin vs. placebo
|
Drug: Prazosin
FDA approved medication for hypertension
|
Show Detailed Description |
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Charles W Meredith, MD | charles.meredith@med.va.gov |
United States, Washington | |||||
VA Puget Sound Health Care System | Recruiting | ||||
Seattle, Washington, United States, 98109 | |||||
Contact: Charles W Meredith, MD charles.meredith@med.va.gov | |||||
Principal Investigator: Andrew J. Saxon, MD |
Principal Investigator: | Andrew J. Saxon, MD | VA Puget Sound Health Care System |
drugs.com PDR information on the study drug 
  |
Responsible Party: | Department of Veterans Affairs ( Saxon, Andrew - Principal Investigator ) |
Study ID Numbers: | REAP 05-0020 |
First Received: | October 13, 2005 |
Last Updated: | August 26, 2008 |
ClinicalTrials.gov Identifier: | NCT00240227 |
Health Authority: | United States: Federal Government |
|
|
|
|
|